If I recall correctly, Marc Voigt's explanation was that IMM's clients are the pharma companies.
He's always espoused the strategy that IMM would focus itself on trials and agency approval, whilst licensing the eventual product marketing to them.
I've not heard anything from him or the company since that indicates that this business model has changed.
The next 6 months or so look like they'll be pretty busy with trial data.
Should be an interesting ride.
.
If I recall correctly, Marc Voigt's explanation was that IMM's...
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.010(2.47%) |
Mkt cap ! $573.7M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 40.8¢ | 39.0¢ | $1.291M | 3.270M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 160217 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 119125 | 4 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |